Theravance Biopharma (TBPH) Total Non-Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Total Non-Current Liabilities data on file, last reported at $181.5 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $181.5 million, up 2.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $181.5 million (up 2.93% YoY), and the FY2025 annual result was $188.5 million, up 98.63% from the prior year.
• Total Non-Current Liabilities eased to $181.5 million in Q1 2026 per TBPH's latest filing, from $188.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $708.2 million in Q2 2022 and troughed at $89.5 million in Q4 2023.
• A 5-year average of $223.8 million and a median of $165.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities tumbled 85.96% in 2022, then jumped 98.63% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $89.6 million in 2022, then dropped by 0.07% to $89.5 million in 2023, then increased by 6.01% to $94.9 million in 2024, then soared by 98.63% to $188.5 million in 2025, then fell by 3.74% to $181.5 million in 2026.
• Business Quant data shows TBPH's Total Non-Current Liabilities at $181.5 million in Q1 2026, $188.5 million in Q4 2025, and $182.5 million in Q3 2025.